Jakub Dvořáček, CEO of the Czech Association of Innovative Pharmaceutical Industry (AIFP), describes the thorough review of the reimbursement scheme the association has worked on alongside other key stakeholders in Czech healthcare and evaluates the major change this will bring in terms of access to innovative medicines for patients. Furthermore, he emphasizes the significant role of an open platform for discussion and negotiation whilst sharing some of the outcomes of the “Innovation for Life” study, which portrays the major benefits that pharmaceutical innovation can bring to the Czech Republic in the long run.
Pharma companies in the Czech Republic grow by double-digits every year. At first, they encounter many difficulties to access the market, but once they achieve that, they grow very fast
